Advertisement: Click here to learn how to Generate Art From Text
publication date: Feb 2, 2024
author/source: AMS Biotechnology (Europe) Ltd
AMSBIO announced a new award scheme for 2024 that will provide travel grants to scientists under thirty years old who are employed in academic institutions, companies or research institutions engaged in cancer research and stem cell research.
AMSBIO, which has worked closely with the life science community around the world for more than three decades, believes in partnership. It also believes in paying it forward by supporting researchers and new research. Last year, AMSBIO funded a grant for ISSCR 2020. The grant scheme was so popular, AMSBIO is offering two grants this year: one for the AACR annual meeting 2024, in San Diego, USA and another for ISSCR annual meeting 2024, in Hamburg, Germany.
Two $1,000 grants will be awarded to young scientists for their travel, accommodation and entry ticket costs, as well as any other expenses they may have while attending AACR or ISSCR in 2024 (7-170th of April)
Marketing Manager, Krystyna Joyce, comments “We are so pleased to be able to offer not only one but two Travel Grants to up-and-coming researchers. We know that attending conferences allows scientists to meet leading experts, network with fellow researchers, and learn about new and innovative research, accelerating their career and scientific progress.”
Please submit your application for the 2024 travel grants scheme. Visit our websiteYou can also provide a summary up to 3000 words describing your stem cell research. If you plan to present a poster, you can submit an abstract instead.
AMSBIO is committed to helping advance stem cell research by providing researchers with the tools and reagents they need to work more efficiently and achieve reliable results faster. Stem cells and in particular human embryonic cells are notoriously unstable cell types. Without careful attention, stem cells can spontaneously divide and undergo genomic rearrangements when in culture. AMSBIO offers researchers a wide range of high-performance, stem-cell optimized and qualified growth media.
About AMS Biotechnology
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products, and services for R&D in the medical, nutrition, cosmetics, and energy industries. AMSBIO has a deep understanding of extracellular matrices and can provide elegant solutions to study cell motility, migration invasion and proliferation. AMSBIO can partner with clients using its expertise in cell cultures and ECM to enhance the screening results of organoids and spheroid models. This includes organ-on-a chip microfluidics. AMSBIO offers recombinant molecules, cell lines, and assays for drug discovery. AMSBIO has a vast and comprehensive biorepository and is widely recognized as a leader in the provision of high-quality specimens from human and animal tissue. The company offers unique clinical grade products that are used in stem cell and cell therapy applications. This includes GMP cryopreservation and high-quality viral delivery solutions.